VEGFA and renal cell carcinoma: Nonetheless, based on the positive results from this phase II study, the combination of lenvatinib and everolimus was recently approved by FDA (May 2016) for the treatment of patients with advanced RCC pretreated with one anti-VEGF therapy (43).